As of September 30, 2026, Elicio Therapeutics, Inc carries a market capitalization of 45.57M, placing it among publicly traded companies globally. Its enterprise value stands at 30.66M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 45.57M |
| Enterprise Value | 30.66M |
Elicio Therapeutics, Inc's next confirmed earnings release is scheduled for March 26, 2027.
| Earnings Date | 3/26/2027 |
As of September 30, 2026, Elicio Therapeutics, Inc has 28.31M shares outstanding.
| Shares Outstanding | 28.31M |
These figures are as of September 30, 2026.
| PB Ratio | 2.74 |
| P/TBV Ratio | 2.74 |
| P/FCF Ratio | -1.01 |
| P/OCF Ratio | -1.01 |
As of September 30, 2026, Elicio Therapeutics, Inc maintains a current ratio of 3.43, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 74.22, indicating elevated leverage, while an interest coverage ratio of -23.73 demonstrates limited ability to service its debt obligations.
| Current Ratio | 3.43 |
| Quick Ratio | 3.11 |
| Debt / Equity | 74.22 |
| Debt / EBITDA | -0.38 |
| Interest Coverage | -23.73 |
Over the twelve months ended September 30, 2026, Elicio Therapeutics, Inc posted a negative return on equity (ROE) of -315.32, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -105.29, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 33.00, a quick read on workforce productivity versus industry peers.
| Return on Equity (ROE) | -315.32 |
| Return on Assets (ROA) | -105.29 |
| Employee Count | 33.00 |
Over the twelve months ended September 30, 2026, Elicio Therapeutics, Inc recorded 48,526.50 in income tax expense. The company reported a pretax loss of -31.48M and -31.53M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | 48,526.50 |
As of the close on November 17, 2026, Elicio Therapeutics, Inc's stock has declined approximately 82.25% over the past 52 weeks. The 50-day moving average sits at 1.58, while the 200-day moving average is 5.42.
| 52-Week Price Change | -82.25% |
| 50-Day Moving Average | 1.58 |
| 200-Day Moving Average | 5.42 |
Over the twelve months ended September 30, 2026, Elicio Therapeutics, Inc generated - - in revenue and converted that into -31.53M in net income, yielding earnings per share of -1.55. EBITDA reached -32.81M, while operating income came in at -33.81M.
| Operating Income | -33.81M |
| Pretax Income | -31.48M |
| Net Income | -31.53M |
| EBITDA | -32.81M |
| EBIT | -33.81M |
| Earnings Per Share (EPS) | -1.55 |
As of September 30, 2026, Elicio Therapeutics, Inc holds 27.26M in cash and equivalents against 12.34M in total debt, resulting in a net debt position of -18.76M. Total book value stands at 16.63M, with working capital of 21.27M providing operational flexibility.
| Cash & Cash Equivalents | 27.26M |
| Total Debt | 12.34M |
| Net Debt | -18.76M |
| Equity (Book Value) | 16.63M |
| Book Value Per Share | 0.59 |
| Working Capital | 21.27M |
Elicio Therapeutics, Inc produced -32.62M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -14,116.80 in capital expenditures, free cash flow totaled -32.63M - equivalent to -1.60 per share.
| Operating Cash Flow | -32.62M |
| Capital Expenditures | -14,116.80 |
| Free Cash Flow | -32.63M |
| FCF Per Share | -1.60 |
These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -99.42: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -91.35, meaning Elicio Therapeutics, Inc raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -91.35 |
| FCF Yield | -99.42 |
Elicio Therapeutics, Inc's most recent stock split took place on June 2, 2023 with a 10:1 split ratio.
| Last Split Date | 6/2/2023 |
| Split Ratio | 10:1 |
As of September 30, 2026, Elicio Therapeutics, Inc has an Altman Z-Score of -10.22, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -10.22 |